Based on our findings of the tumor-promoting effects of anti-CD1d monoclonal antibody treatment of CD1d-expressing tumor cells, current therapeutic strategies based on globally inhibiting CD1d by antibody blockade are not recommended. The gene discussed is CD1D; the disease is neoplasm.